HomeCompareZGXNF vs ABBV

ZGXNF vs ABBV: Dividend Comparison 2026

ZGXNF yields 2.43% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZGXNF wins by $152.94M in total portfolio value· pulled ahead in Year 3
10 years
ZGXNF
ZGXNF
● Live price
2.43%
Share price
$3.06
Annual div
$0.07
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$153.04M
Annual income
$141,837,707.22
Full ZGXNF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ZGXNF vs ABBV

📍 ZGXNF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZGXNFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZGXNF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZGXNF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZGXNF
Annual income on $10K today (after 15% tax)
$206.67/yr
After 10yr DRIP, annual income (after tax)
$120,562,051.14/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ZGXNF beats the other by $120,540,995.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZGXNF + ABBV for your $10,000?

ZGXNF: 50%ABBV: 50%
100% ABBV50/50100% ZGXNF
Portfolio after 10yr
$76.57M
Annual income
$70,931,239.49/yr
Blended yield
92.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ZGXNF
No analyst data
Altman Z
3.7
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZGXNF buys
0
ABBV buys
0
No recent congressional trades found for ZGXNF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZGXNFABBV
Forward yield2.43%3.06%
Annual dividend / share$0.07$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$153.04M$102.3K
Annual income after 10y$141,837,707.22$24,771.77
Total dividends collected$152.18M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ZGXNF vs ABBV ($10,000, DRIP)

YearZGXNF PortfolioZGXNF Income/yrABBV PortfolioABBV Income/yrGap
1$11,186$486.27$11,550$430.00$364.00ABBV
2$12,986$1,016.75$13,472$627.96$486.00ABBV
3← crossover$16,101$2,206.23$15,906$926.08+$195.00ZGXNF
4$22,341$5,113.07$19,071$1,382.55+$3.3KZGXNF
5$37,166$13,261.06$23,302$2,095.81+$13.9KZGXNF
6$81,003$41,234.77$29,150$3,237.93+$51.9KZGXNF
7$254,654$167,980.64$37,536$5,121.41+$217.1KZGXNF
8$1,259,566$987,086.10$50,079$8,338.38+$1.21MZGXNF
9$10,473,558$9,125,822.70$69,753$14,065.80+$10.40MZGXNF
10$153,044,414$141,837,707.22$102,337$24,771.77+$152.94MZGXNF

ZGXNF vs ABBV: Complete Analysis 2026

ZGXNFStock

ZIGExN Co., Ltd. operates the life media platform in Japan. It operates Job change EX, a job change and job information site; Dispatch EX, a Website covering job information and dispatch company information of staffing sites and dispatching companies; Part-timer EX, a part time job search service site; d job, a job recruitment information and smartphone work recruitment service; Nurse Job EX, a nurse recruitment/career change site; and Pharmacist Job EX, a pharmacist recruitment information search site. The company also offers Rental Smocca, a search site for real estate rental housing listings; Maisumi EX, a site specialized in real estate sale, land utilization, and rental management; and Moving estimate EX, a site that offers moving estimates. In addition, it provides SmaRE, a marketing support tool for the purchase and sale of real estate properties; Minorino, a used condominium sales portal site specializing in renovation; and Provider EX, a comparison site that helps in selecting high-speed mobile communication. Further, the company offers used car EX, an used car information site; Car purchase EX, a comparison site for car purchase; Car-tana, a used car export portal site; Apple world, a portal for hotel booking; Hotelista, a hotel reservation Website; Travery, a comparison site for hotel reservations; and tradecarview, a used car export site. In addition it offers Puronuri, a service that allows to collect information and compare estimates for exterior wall painting; Exterior wall painting concierge is a free matching service; Enepi a price comparison service; Guriene, a service that supports the smart and profitable introduction of solar power generation; Hotelista, a hotel reservation site; Traveler, a comparison / reservation site for low-cost flights and LCCs; Nursery rhyme, a baby sitter service; and franchise, marriage, tutor, and study abroad comparison sites. ZIGExN Co., Ltd. was founded in 2006 and is headquartered in Tokyo, Japan.

Full ZGXNF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ZGXNF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZGXNF vs SCHDZGXNF vs JEPIZGXNF vs OZGXNF vs KOZGXNF vs MAINZGXNF vs JNJZGXNF vs MRKZGXNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.